Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is a randomized, placebo-controlled, double-blind study investigating whether the
medication Ambroxol is safe,effectiveness and well tolerated for the treatment of Lewy Body
Dementia (LBD). Currently the main treatments for patients with LBD target symptom
management. However, none of the medications treat the underlying cause of the disease, which
includes the accumulation of protein in the brain. Therefore, even if patients respond well
to symptomatic treatment, they continue to deteriorate. Therefore, the purpose of the current
study is to make sure Ambroxol is safe to take long term and to test the effects of Ambroxol
in treating the cognitive impairments associated with LBD by modifying the underlying causes
of the disease.
There will be a total of 15 people participating this this study, which will last 52 weeks.
Over the study period patients will undergo clinical, neuropsychological and neuroimaging
assessment to assess changes.